Researchers used the Tennessee Medicaid database linked to Medicare and Active Bacterial Core surveillance system databases. They studied 1,233 case patients with invasive pneumococcal disease, aged 5 years and older, matched to 24,399 control participants.
They defined invasive pneumococcal disease by the isolation of Streptococcus pneumoniae from a normally sterile site.
Researchers found case patients had greater odds of being current opioid users as compared to control participants. Association of opioid use and invasive pneumococcal disease was the strongest for opioids that:
• Were long acting
• Of high potency
• Were used at high dosages
“[Opioid use] represents a novel risk factor for [invasive pneumococcal] diseases,” study authors concluded.
More articles on opioids:
Cost of US opioid crisis exceeds $1T since 2001: 3 insights
5 opioid makers paid $8M+ to pain groups since 2012: 7 things to know
7 recent opioid epidemic lawsuits
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
